149 related articles for article (PubMed ID: 37708209)
1. Prediction of pathological complete response to neoadjuvant chemotherapy in locally advanced breast cancer by using a deep learning model with 18F-FDG PET/CT.
Bulut G; Atilgan HI; Çınarer G; Kılıç K; Yıkar D; Parlar T
PLoS One; 2023; 18(9):e0290543. PubMed ID: 37708209
[TBL] [Abstract][Full Text] [Related]
2. The Value of 18F-FDG PET/CT Imaging Combined With Pretherapeutic Ki67 for Early Prediction of Pathologic Response After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer.
Luo J; Zhou Z; Yang Z; Chen X; Cheng J; Shao Z; Guo X; Tuan J; Fu X; Yu X
Medicine (Baltimore); 2016 Feb; 95(8):e2914. PubMed ID: 26937935
[TBL] [Abstract][Full Text] [Related]
3. 18F-fluorodeoxyglucose (FDG) PET/CT after two cycles of neoadjuvant therapy may predict response in HER2-negative, but not in HER2-positive breast cancer.
Cheng J; Wang Y; Mo M; Bao X; Zhang Y; Liu G; Zhang J; Geng D
Oncotarget; 2015 Oct; 6(30):29388-95. PubMed ID: 26336821
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Role of Early and End-of-Neoadjuvant Treatment 18F-FDG PET/CT in Patients With Breast Cancer.
García Vicente AM; Amo-Salas M; Relea Calatayud F; Muñoz Sánchez Mdel M; Pena Pardo FJ; Jiménez Londoño GA; Álvarez Cabellos R; Espinosa Aunión R; Soriano Castrejón Á
Clin Nucl Med; 2016 Jul; 41(7):e313-22. PubMed ID: 26953659
[TBL] [Abstract][Full Text] [Related]
5. Predictive and prognostic potential of volume-based metabolic variables obtained by a baseline
Garcia-Vicente AM; Pérez-Beteta J; Amo-Salas M; Molina D; Jimenez-Londoño GA; Soriano-Castrejón AM; Pena Pardo FJ; Martínez-González A
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2018; 37(2):73-79. PubMed ID: 29102649
[TBL] [Abstract][Full Text] [Related]
6. FDG-PET/CT and MRI for Evaluation of Pathologic Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer: A Meta-Analysis of Diagnostic Accuracy Studies.
Sheikhbahaei S; Trahan TJ; Xiao J; Taghipour M; Mena E; Connolly RM; Subramaniam RM
Oncologist; 2016 Aug; 21(8):931-9. PubMed ID: 27401897
[TBL] [Abstract][Full Text] [Related]
7. Predicting Response to Neoadjuvant Chemotherapy Using 18F FDG PET-CT in Patients with Locally Advanced Breast Cancer.
Hulikal N; Gajjala SR; Kalawat T; Kadiyala S; Kottu R
Asian Pac J Cancer Prev; 2020 Jan; 21(1):93-98. PubMed ID: 31983170
[TBL] [Abstract][Full Text] [Related]
8. Intratumoral heterogeneity in
Molina-García D; García-Vicente AM; Pérez-Beteta J; Amo-Salas M; Martínez-González A; Tello-Galán MJ; Soriano-Castrejón Á; Pérez-García VM
Ann Nucl Med; 2018 Jul; 32(6):379-388. PubMed ID: 29869770
[TBL] [Abstract][Full Text] [Related]
9. Can FDG-PET/CT predict early response to neoadjuvant chemotherapy in breast cancer?
Andrade WP; Lima EN; Osório CA; do Socorro Maciel M; Baiocchi G; Bitencourt AG; Fanelli MF; Damascena AS; Soares FA
Eur J Surg Oncol; 2013 Dec; 39(12):1358-63. PubMed ID: 24120422
[TBL] [Abstract][Full Text] [Related]
10. Predicting neo-adjuvant chemotherapy response and progression-free survival of locally advanced breast cancer using textural features of intratumoral heterogeneity on F-18 FDG PET/CT and diffusion-weighted MR imaging.
Yoon HJ; Kim Y; Chung J; Kim BS
Breast J; 2019 May; 25(3):373-380. PubMed ID: 29602210
[TBL] [Abstract][Full Text] [Related]
11. PET/CT radiomics in breast cancer: promising tool for prediction of pathological response to neoadjuvant chemotherapy.
Antunovic L; De Sanctis R; Cozzi L; Kirienko M; Sagona A; Torrisi R; Tinterri C; Santoro A; Chiti A; Zelic R; Sollini M
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1468-1477. PubMed ID: 30915523
[TBL] [Abstract][Full Text] [Related]
12. The Role of 18F-FDG PET/CT in Predicting the Neoadjuvant Treatment Response in Patients with Locally Advanced Breast Cancer.
Goktas Aydin S; Bilici A; Olmez OF; Oven BB; Acikgoz O; Cakir T; Basim P; Cakir A; Kutlu Y; Hamdard J
Breast Care (Basel); 2022 Oct; 17(5):470-479. PubMed ID: 36684400
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Magnetic Resonance Imaging With Positron Emission Tomography/Computed Tomography in the Evaluation of Response to Neoadjuvant Therapy of Breast Cancer.
Baysal H; Serdaroglu AY; Ozemir IA; Baysal B; Gungor S; Erol CI; Ozsoy MS; Ekinci O; Alimoglu O
J Surg Res; 2022 Oct; 278():223-232. PubMed ID: 35636197
[TBL] [Abstract][Full Text] [Related]
14. Textural features of
Cheng L; Zhang J; Wang Y; Xu X; Zhang Y; Zhang Y; Liu G; Cheng J
Ann Nucl Med; 2017 Aug; 31(7):544-552. PubMed ID: 28646331
[TBL] [Abstract][Full Text] [Related]
15. Subtype-Guided
Wu S; Wang Y; Li J; Zhang N; Mo M; Klimberg S; Kaklamani V; Cochet A; Shao Z; Cheng J; Liu G
Oncologist; 2020 Apr; 25(4):e626-e633. PubMed ID: 32297448
[TBL] [Abstract][Full Text] [Related]
16. Tumor metabolism assessed by FDG-PET/CT and tumor proliferation assessed by genomic grade index to predict response to neoadjuvant chemotherapy in triple negative breast cancer.
Groheux D; Biard L; Lehmann-Che J; Teixeira L; Bouhidel FA; Poirot B; Bertheau P; Merlet P; Espié M; Resche-Rigon M; Sotiriou C; de Cremoux P
Eur J Nucl Med Mol Imaging; 2018 Jul; 45(8):1279-1288. PubMed ID: 29616304
[TBL] [Abstract][Full Text] [Related]
17.
Li P; Wang X; Xu C; Liu C; Zheng C; Fulham MJ; Feng D; Wang L; Song S; Huang G
Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1116-1126. PubMed ID: 31982990
[TBL] [Abstract][Full Text] [Related]
18. Changes in 18F-FDG-PET/CT tumor metabolism are not consistent with pathologic complete response in hormone-positive breast cancer.
Kaya S; Aktas B; Tanrikulu Sismek E; Akif Ozturk M; Dede F; Kaya H; Ugurlu U; Ozgen Z; Koca S; Halil S; Hasanov R; Alan O; Akgul Babacan N; Ercelep O; Dane F; Gumus M; Yumuk F
J BUON; 2017; 22(5):1191-1198. PubMed ID: 29135102
[TBL] [Abstract][Full Text] [Related]
19. Prognostic impact of 18F-FDG PET/CT staging and of pathological response to neoadjuvant chemotherapy in triple-negative breast cancer.
Groheux D; Giacchetti S; Delord M; de Roquancourt A; Merlet P; Hamy AS; Espié M; Hindié E
Eur J Nucl Med Mol Imaging; 2015 Mar; 42(3):377-85. PubMed ID: 25432784
[TBL] [Abstract][Full Text] [Related]
20. Predictive value of
Chen K; Wang J; Li S; Zhou W; Xu W
Eur J Nucl Med Mol Imaging; 2023 Jun; 50(7):1869-1880. PubMed ID: 36808002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
